Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences:

• Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET
• Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. ET

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start times to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conferences.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005153/en/

Investors:
Matt Roache, 617-621-8395
Director, Investor Relations
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• The Toro Company Reports Record Third-Quarter Results
• Yardstick Institute Returns for 9th Edition, Uniting Executives Around "The Future Is Human"
• Antea Group USA Named Accredited EcoVadis Consulting Partner